Agonis reseptor glucagon-like peptide-1 (GLP-1RA), seperti semaglutide dan liraglutide, diduga bermanfaat untuk obstructive sleep apnea (OSA) karena dapat memperbaiki pola dan stabilitas...(Baca Selengkapnya)

Glucagon like peptide-1 Receptor Agonist (GLP-1RA) merupakan salah satu agen incretin based therapy. GLP-1RA sudah direkomendasikan oleh American Diabetes Association dan European...(Baca Selengkapnya)

Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide Hathaway JT, Shah MP, Hathaway DB, Zekavat SM, Krasniqi D, Gittinger...(Baca Selengkapnya)

Cardiovascular and mortality outcomes with GLP‑1 receptor agonists vs other glucose‑lowering drugs in individuals with NAFLD and type 2 diabetes: a large...(Baca Selengkapnya)

Risk of Stroke in Real-World US Individuals with Type 2 Diabetes Receiving Semaglutide or a Dipeptidyl Peptidase 4 Inhibitor Evans M, Husain...(Baca Selengkapnya)

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, Sanyal...(Baca Selengkapnya)

Liraglutide Versus Semaglutide For Weight Reduction-A Cost Needed To Treat Analysis Azuri J, Hammerman A, Aboalhasan E, Sluckis B, Arbel R. Obesity...(Baca Selengkapnya)

Semaglutide 2.4 mg/wk for Weight Loss in Patients with Severe Obesity and with or without a History of Bariatric Surgery Bonnet JB, Tournayre...(Baca Selengkapnya)

Semaglutide dilaporkan dapat menurunkan berat badan pada pasien obesitas meskipun obesitas tersebut tidak disertai diabetes mellitus. Semaglutide merupakan suatu agonis reseptor glucagon-like peptide-1 atau...(Baca Selengkapnya)

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó...(Baca Selengkapnya)